Long D Pham

Array ( [id] => 18034656 [patent_doc_number] => 20220378871 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-12-01 [patent_title] => Muscle Tissue-Regenerating Agent [patent_app_type] => utility [patent_app_number] => 17/765342 [patent_app_country] => US [patent_app_date] => 2020-09-30 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 24453 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -14 [patent_words_short_claim] => 10 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17765342 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16555771 [patent_doc_number] => 20210000919 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-01-07 [patent_title] => ACTIVATORS OF CXCR3 FOR THE TREATMENT OF ANGIOPATHIES OF THE EYE [patent_app_type] => utility [patent_app_number] => 17/025572 [patent_app_country] => US [patent_app_date] => 2020-09-18 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 9733 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -17 [patent_words_short_claim] => 26 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17025572 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17648565 [patent_doc_number] => 11351268 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2022-06-07 [patent_title] => FGF21 C-terminal peptide optimization [patent_app_type] => utility [patent_app_number] => 16/983726 [patent_app_country] => US [patent_app_date] => 2020-08-03 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 22 [patent_figures_cnt] => 22 [patent_no_of_words] => 39684 [patent_no_of_claims] => 7 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 39 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16983726 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16419800 [patent_doc_number] => 20200344998 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-11-05 [patent_title] => PEGYLATED ANTIFREEZE PROTEINS AND METHODS OF MAKING AND USING THE SAME [patent_app_type] => utility [patent_app_number] => 16/933535 [patent_app_country] => US [patent_app_date] => 2020-07-20 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 9877 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -18 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16933535 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16581484 [patent_doc_number] => 20210015886 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-01-21 [patent_title] => COMPOSITION FOR IMPROVING MILD COGNITIVE IMPAIRMENT AND METHOD FOR IMPROVING MILD COGNITIVE IMPAIRMENT [patent_app_type] => utility [patent_app_number] => 16/931979 [patent_app_country] => US [patent_app_date] => 2020-07-17 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 2568 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -3 [patent_words_short_claim] => 56 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16931979 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18510037 [patent_doc_number] => 20230226135 [patent_country] => US [patent_kind] => A9 [patent_issue_date] => 2023-07-20 [patent_title] => ACETYLCHOLINE MODULATION OF IMMUNE FUNCTION [patent_app_type] => utility [patent_app_number] => 17/627359 [patent_app_country] => US [patent_app_date] => 2020-07-16 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 26940 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -65 [patent_words_short_claim] => 33 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17627359 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18510037 [patent_doc_number] => 20230226135 [patent_country] => US [patent_kind] => A9 [patent_issue_date] => 2023-07-20 [patent_title] => ACETYLCHOLINE MODULATION OF IMMUNE FUNCTION [patent_app_type] => utility [patent_app_number] => 17/627359 [patent_app_country] => US [patent_app_date] => 2020-07-16 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 26940 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -65 [patent_words_short_claim] => 33 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17627359 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16397357 [patent_doc_number] => 20200338215 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-10-29 [patent_title] => DISULFIDE-LINKED POLYETHYLENEGLYCOL/PEPTIDE CONJUGATES FOR THE TRANSFECTION OF NUCLEIC ACIDS [patent_app_type] => utility [patent_app_number] => 16/929766 [patent_app_country] => US [patent_app_date] => 2020-07-15 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 37630 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -15 [patent_words_short_claim] => 280 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16929766 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16539394 [patent_doc_number] => 20200405807 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-12-31 [patent_title] => Compositions and Formulations and Methods of Production and Use Thereof [patent_app_type] => utility [patent_app_number] => 16/918167 [patent_app_country] => US [patent_app_date] => 2020-07-01 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 165750 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -18 [patent_words_short_claim] => 112 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16918167 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16359461 [patent_doc_number] => 20200316212 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-10-08 [patent_title] => METHODS OF TREATING CANCER USING COMPOUNDS CONTAINING A VASCULAR DISRUPTING AGENT [patent_app_type] => utility [patent_app_number] => 16/946391 [patent_app_country] => US [patent_app_date] => 2020-06-19 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 10717 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -22 [patent_words_short_claim] => 36 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16946391 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17513696 [patent_doc_number] => 11292826 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2022-04-05 [patent_title] => Hybrid ActRIIB ligand trap proteins for treating muscle wasting diseases [patent_app_type] => utility [patent_app_number] => 16/895670 [patent_app_country] => US [patent_app_date] => 2020-06-08 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 12 [patent_figures_cnt] => 12 [patent_no_of_words] => 33829 [patent_no_of_claims] => 16 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 33 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16895670 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17748227 [patent_doc_number] => 20220226430 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-07-21 [patent_title] => PROTEIN INHIBITORS OF CLOSTRIDIUM DIFFICILE TOXIN B [patent_app_type] => utility [patent_app_number] => 17/609818 [patent_app_country] => US [patent_app_date] => 2020-05-11 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 8991 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -17 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17609818 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18274629 [patent_doc_number] => 11613560 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2023-03-28 [patent_title] => Bicyclic peptide ligands specific for OX40 [patent_app_type] => utility [patent_app_number] => 16/872097 [patent_app_country] => US [patent_app_date] => 2020-05-11 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 2 [patent_figures_cnt] => 3 [patent_no_of_words] => 15769 [patent_no_of_claims] => 26 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 246 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16872097 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16376369 [patent_doc_number] => 20200325211 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-10-15 [patent_title] => RECOMBINANT ELASTIN AND PRODUCTION THEREOF [patent_app_type] => utility [patent_app_number] => 16/844226 [patent_app_country] => US [patent_app_date] => 2020-04-09 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 21381 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -19 [patent_words_short_claim] => 63 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16844226 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17020927 [patent_doc_number] => 20210244798 [patent_country] => US [patent_kind] => A9 [patent_issue_date] => 2021-08-12 [patent_title] => ACYLATED GLP-1/GLP-2 DUAL AGONISTS [patent_app_type] => utility [patent_app_number] => 16/841104 [patent_app_country] => US [patent_app_date] => 2020-04-06 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 17021 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -45 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16841104 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17020927 [patent_doc_number] => 20210244798 [patent_country] => US [patent_kind] => A9 [patent_issue_date] => 2021-08-12 [patent_title] => ACYLATED GLP-1/GLP-2 DUAL AGONISTS [patent_app_type] => utility [patent_app_number] => 16/841104 [patent_app_country] => US [patent_app_date] => 2020-04-06 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 17021 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -45 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16841104 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16878015 [patent_doc_number] => 11028148 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2021-06-08 [patent_title] => Recombinant collagen and elastin molecules and uses thereof [patent_app_type] => utility [patent_app_number] => 16/839042 [patent_app_country] => US [patent_app_date] => 2020-04-02 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 5 [patent_figures_cnt] => 5 [patent_no_of_words] => 27264 [patent_no_of_claims] => 19 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 27 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16839042 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17323614 [patent_doc_number] => 11214609 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2022-01-04 [patent_title] => Recombinant collagen and elastin molecules and uses thereof [patent_app_type] => utility [patent_app_number] => 16/839035 [patent_app_country] => US [patent_app_date] => 2020-04-02 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 5 [patent_figures_cnt] => 5 [patent_no_of_words] => 27241 [patent_no_of_claims] => 19 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 69 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16839035 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17503493 [patent_doc_number] => 20220096595 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-03-31 [patent_title] => ANTI-ATOPIC DERMATITIS PROTEIN [patent_app_type] => utility [patent_app_number] => 17/427109 [patent_app_country] => US [patent_app_date] => 2020-03-30 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 2272 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -3 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17427109 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17702891 [patent_doc_number] => 20220202897 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-06-30 [patent_title] => USE OF CYCLO(HIS-PRO) (CHP) FOR PREVENTING, AMELIORATING, OR TREATING FIBROSIS [patent_app_type] => utility [patent_app_number] => 17/599211 [patent_app_country] => US [patent_app_date] => 2020-03-30 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 11954 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -9 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17599211 [rel_patent_id] =>[rel_patent_doc_number] =>)